Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab plus sintilimab in second-line advanced esophageal squamous cell carcinoma
ChiCTR2100041780Phase 2Recruiting
- Sponsor
- The Sixth Medical Center of the Chinese People's Liberation Army General Hospital
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab and sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The Sixth Medical Center of the Chinese People's Liberation Army General Hospital. Primary endpoints: Tumor size, Overall survival and 1 more. Started Jan 2021; status: recruiting.
02
Drugs
nimotuzumabsintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100041780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041780.